Miransertib mesylate is a non-ATP competitive, selective AKT inhibitor that suppresses the PI3K/AKT pathway. This inhibition can impede tumor cell proliferation and promote apoptosis, as demonstrated in cellular assays and in vivo models of cancers like Proteus syndrome and various carcinomas.
Molekulargewicht:
624.73
CAS Nummer:
[1817727-88-0]
Formel:
C29H32N6O6S2
Target-Kategorie:
Others
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
